Technical Analysis for IVX - Invion Ltd
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.200 | 9900.00% | 0.198 |
Earnings due: Nov 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 9900.00% | |
Fell Below 50 DMA | Bearish | 9900.00% | |
Boomer Buy Setup | Bullish Swing Setup | 9900.00% | |
Narrow Range Bar | Range Contraction | 9900.00% | |
Wide Bands | Range Expansion | 9900.00% | |
Gapped Down | Weakness | 9900.00% | |
Jack-in-the-Box Bearish | Bearish Swing Setup | 6566.67% | |
Crossed Above 20 DMA | Bullish | 6566.67% | |
Crossed Above 50 DMA | Bullish | 6566.67% | |
180 Bullish Setup | Bullish Swing Setup | 6566.67% |
Alert | Time |
---|---|
3x Volume Pace | 3 days ago |
Down 10% | 3 days ago |
Gapped Down (Full) | 3 days ago |
Down 1 ATR | 3 days ago |
2x Volume Pace | 3 days ago |
Get this analysis on your stocks daily!
Invion Ltd Description
Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Chemistry Disease Diseases Life Sciences Protein Reversal Drug Development Helium Chemical Compounds Organic Compounds Omeo Inflammation Respiratory Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Date | Title |
---|---|
Oct 25 | ASX Penny Stocks To Watch In October 2024 |
Indicator | Value |
---|---|
52 Week High | 0.008 |
52 Week Low | 0.002 |
Average Volume | 5,302,042 |
200-Day Moving Average | 0.004 |
50-Day Moving Average | 0.002 |
20-Day Moving Average | 0.002 |
10-Day Moving Average | 0.002 |
Average True Range | 0.001 |
RSI (14) | 47.37 |
ADX | 37.96 |
+DI | 25.000 |
-DI | 9.722 |
Chandelier Exit (Long, 3 ATRs) | 0.001 |
Chandelier Exit (Short, 3 ATRs) | 0.004 |
Upper Bollinger Bands | 0.003 |
Lower Bollinger Band | 0.002 |
Percent B (%b) | 0.36 |
BandWidth | 63.636 |
MACD Line | 0.000 |
MACD Signal Line | 0.000 |
MACD Histogram | -0.0001 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.002 | ||||
Resistance 3 (R3) | 0.002 | 0.002 | 0.002 | ||
Resistance 2 (R2) | 0.002 | 0.002 | 0.002 | 0.002 | |
Resistance 1 (R1) | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Pivot Point | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Support 1 (S1) | 0.002 | 0.002 | 0.002 | 0.002 | 0.002 |
Support 2 (S2) | 0.002 | 0.002 | 0.002 | 0.002 | |
Support 3 (S3) | 0.002 | 0.002 | 0.002 | ||
Support 4 (S4) | 0.002 |